NewsBenzinga据报道,Climb Bio 公布了初步 pMN II 期数据:200 mg budoprutug 在第 12 周使 PLA2R 抗体平均降低 70%,并在 13 名患者中的 5 名实现免疫学缓解,适用于 pMN。 据报道,Climb Bio 公布了初步 pMN II 期数据:200 mg budoprutug 在第 12 周使 PLA2R 抗体平均降低 70%,并在 13 名患者中的 5 名实现免疫学缓解,适用于 pMN。 Benzinga 2026.10.26 06:42 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Z Squared Secures 5-Yr Option To Acquire Nearly 90 Acres Near Arkansas Campus, Terms Undisclosed Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday Truist Securities Downgrades Lucky Strike to Hold, Lowers Price Target to $4.35